Edward James1, Joachim Keppler2, Thomas L Robertshaw1, Ben Sessa3. 1. School of Pharmacy and Pharmaceutical Sciences, Cardiff University, Cardiff, UK. 2. Department of Consciousness Research, DIWISS, Roth, Germany. 3. Centre for Neuropsychopharmacology, Division of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
Abstract
OBJECTIVE: Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post-traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N-dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of selected literature regarding the mechanisms of action of DMT and ayahuasca; and assess to what extent the state of research can explain reports of unusual phenomenology. DESIGN: A narrative review. RESULTS: Compounds in ayahuasca have been found to bind to serotonergic receptors, glutaminergic receptors, sigma-1 receptors, trace amine-associated receptors, and modulate BDNF expression and the dopaminergic system. Subjective effects are associated with increased delta and theta oscillations in amygdala and hippocampal regions, decreased alpha wave activity in the default mode network, and stimulations of vision-related brain regions particularly in the visual association cortex. Both biological processes and field of consciousness models have been proposed to explain subjective effects of DMT and ayahuasca, however, the evidence supporting the proposed models is not sufficient to make confident conclusions. Ayahuasca plant medicine and DMT represent potentially novel treatment modalities. CONCLUSIONS: Further research is required to clarify the mechanisms of action and develop treatments which can be made available to the general public. Integration between healthcare research institutions and reputable practitioners in the Amazon is recommended.
OBJECTIVE: Reports have indicated possible uses of ayahuasca for the treatment of conditions including depression, addictions, post-traumatic stress disorder, anxiety and specific psychoneuroendocrine immune system pathologies. The article assesses potential ayahuasca and N,N-dimethyltryptamine (DMT) integration with contemporary healthcare. The review also seeks to provide a summary of selected literature regarding the mechanisms of action of DMT and ayahuasca; and assess to what extent the state of research can explain reports of unusual phenomenology. DESIGN: A narrative review. RESULTS: Compounds in ayahuasca have been found to bind to serotonergic receptors, glutaminergic receptors, sigma-1 receptors, trace amine-associated receptors, and modulate BDNF expression and the dopaminergic system. Subjective effects are associated with increased delta and theta oscillations in amygdala and hippocampal regions, decreased alpha wave activity in the default mode network, and stimulations of vision-related brain regions particularly in the visual association cortex. Both biological processes and field of consciousness models have been proposed to explain subjective effects of DMT and ayahuasca, however, the evidence supporting the proposed models is not sufficient to make confident conclusions. Ayahuasca plant medicine and DMT represent potentially novel treatment modalities. CONCLUSIONS: Further research is required to clarify the mechanisms of action and develop treatments which can be made available to the general public. Integration between healthcare research institutions and reputable practitioners in the Amazon is recommended.
Authors: J Riba; A Rodríguez-Fornells; G Urbano; A Morte; R Antonijoan; M Montero; J C Callaway; M J Barbanoj Journal: Psychopharmacology (Berl) Date: 2001-02 Impact factor: 4.530
Authors: Will Lawn; Jaime E Hallak; Jose A Crippa; Rafael Dos Santos; Lilla Porffy; Monica J Barratt; Jason A Ferris; Adam R Winstock; Celia J A Morgan Journal: Sci Rep Date: 2017-11-09 Impact factor: 4.379
Authors: Gabriela de Oliveira Silveira; Rafael Guimarães Dos Santos; Felipe Rebello Lourenço; Giordano Novak Rossi; Jaime E C Hallak; Mauricio Yonamine Journal: Molecules Date: 2020-04-29 Impact factor: 4.411
Authors: Christopher Timmermann; Hannes Kettner; Chris Letheby; Leor Roseman; Fernando E Rosas; Robin L Carhart-Harris Journal: Sci Rep Date: 2021-11-23 Impact factor: 4.379
Authors: Uyen B Chu; Sevahn K Vorperian; Kenneth Satyshur; Kelsey Eickstaedt; Nicholas V Cozzi; Timur Mavlyutov; Abdol R Hajipour; Arnold E Ruoho Journal: Biochemistry Date: 2014-04-28 Impact factor: 3.162